A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...